Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.59 |
| ▸ | RAB9A | P51151 | 10/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.58 |
| ▸ | MLLT1 | Q03111 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17374171 | 0.95 | NPC1 (0.55) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17374183 | 0.92 | RAB9A (0.55) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17374180 | 0.92 | RAB9A (0.55) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17374428 | 0.92 | RAB9A (0.55) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17381902 | 0.89 | NPC1 (0.60) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17374601 | 0.84 | RAB9A (0.53) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL17374599 | 0.84 | RAB9A (0.53) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL19239570 | 0.84 | NPC1 (0.59) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL20200063 | 0.83 | RAB9A (0.54) | NPC1RAB9AS1PR1MLLT1USP30 | |
| SCHEMBL20200054 | 0.83 | RAB9A (0.54) | NPC1RAB9AS1PR1MLLT1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | claimed |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2019-01-24 | — | — | US | claimed |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | claimed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | claimed |
| EP-3157917-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3157917-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2019-01-24 | — | — | US | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | NPC1 463/4885RAB9A 1690/4885S1PR1 1064/4885 |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.